18 May 2023 12:00
MGC Pharmaceuticals Ltd.
PDMR Notification
18 May 2023
ASX, LSE: MXC
MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') wishes to advise that the following Persons Discharging Managerial Responsibilities (PDMR) have dealt with shares in MGC Pharma, and this notification is made in accordance the UK Market Abuse Regulations.
1 | Details of the person discharging managerial responsibilities/person closely associated
| ||||
(a) | Name | Nicole Godresse | |||
2 | Reason for the notification
| ||||
(a) | Position
| Global Chief Sales Officer MGC Medical
| |||
(b) | Initial notification/amendment
| Initial | |||
(c) | If amendment: reason
| n/a | |||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
Full name of entity | MGC Pharmaceuticals Limited
| ||||
Legal Entity Identifier Code | 213800HRE3FQJ6RK4H10
| ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
| ||||
(a) | Description of the financial instrument, type of instrument | Fully Paid Ordinary Shares | |||
(b) | Identification Code (ISIN)
| AU000000MXC6 | |||
(c) | Nature of transaction | Disposal of shares
| |||
(d) | Currency | Price | Volume | Total | |
AUD | $0.007 | 876,636 | $6,136 | ||
Aggregated information | |||||
AUD | $0.007 | 876,636 | $6,136 | ||
(e) | Date of transaction | 2023-05-16 | |||
(f) | Place of transaction | Australian Stock Exchange | |||
1 | Details of the person discharging managerial responsibilities/person closely associated
| ||||
(a) | Name | Amir Polak | |||
2 | Reason for the notification
| ||||
(a) | Position
| Chief Pharmaceutical Development Officer | |||
(b) | Initial notification/amendment
| Initial | |||
(c) | If amendment: reason
| n/a | |||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
Full name of entity | MGC Pharmaceuticals Limited
| ||||
Legal Entity Identifier Code | 213800HRE3FQJ6RK4H10
| ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
| ||||
(a) | Description of the financial instrument, type of instrument | Fully Paid Ordinary Shares | |||
(b) | Identification Code (ISIN)
| AU000000MXC6 | |||
(c) | Nature of transaction | Disposal of shares
| |||
(d) | Currency | Price | Volume | Total | |
AUD | $0.007 | 500,000 | $3,500 | ||
Aggregated information | |||||
AUD | $0.007 | 500,000 | $3,500 | ||
(e) | Date of transaction | 2023-05-17 | |||
(f) | Place of transaction | Australian Stock Exchange | |||
--Ends-
Authorised for release by the Managing Director, for further information please contact:
MGC Pharmaceuticals Ltd Roby Zomer CEO & Managing Director +61 8 6382 3390 info@mgcpharma.co.uk | MGC Pharmaceuticals Ltd Arron Canicais / Rowan Harland Joint Company Secretaries +61 8 6382 3390 info@mgcpharma.co.uk |
UK PR Advisors Tavistock Charles Vivian / Tim Pearson +44 207 920 3150 mgcpharma@tavistock.co.uk | UK Brokers Peterhouse Capital Charles Goodfellow / Lucy Williams +44 207 469 0930 cg@peterhousecap.com / lw@peterhousecap.com |
UK Financial and Corporate Advisor SW4 Partners Rupert Fane / Nilesh Patel rupert@sw4partners.com / nilesh@sw4partners.com |